Marinus Pharmaceuticals (MRNS) Reports Q2 Loss, Misses Revenue Estimates

Marinus Pharmaceuticals (MRNS) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of$ 0.59. This compares to loss of $0.61 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -1.69%. A quarter ago, it was expected that this epilepsy drug developer would post a loss of$ 0.68 per share when it actually produced a loss of $0.68, delivering no surprise. Over the last four quarters, the com ...